BioDelivery Sciences International announced Thursday that it has entered into an agreement with Quintiles to have it support the anticipated launch of Bunavail, BioDelivery Sciences treatment for opioid dependence.
Assuming the drug wins regulatory approval this summer, Raleigh-based BioDelivery Sciences intends to launch the drug in the third quarter of this year.
Under its agreement with Quintiles, the Durham pharmaceutical services company will support the recruitment, training and deployment of a sales force to reach physicians. BioDelivery Sciences estimates nearly 5,000 physicians are responsible for roughly 90 percent of the prescriptions for treatment of opioid dependence.
BioDelivery Sciences expects to hear back from the Food and Drug Administration about its new drug application for Bunavail on June 7.
In February, the company raised $60 million by selling a block of shares to a group of institutional investors. The proceeds are to pay for the commercialization of Bunavail.